Vanda Pharmaceuticals stock stays centered on its core business. Nasdaq-listed VNDA keeps a US investor base.

Vanda Pharmaceuticals Inc. (ISIN US92178N1054) is a Nasdaq-listed biopharmaceutical company with a US investor base and a business centered on central nervous system treatments. Its shares trade under the VNDA ticker, and the company continues to operate through its commercial portfolio and development pipeline.

Business footing

Vanda's model combines marketed medicines with research and development, a structure that gives investors both product revenue exposure and pipeline optionality. The company describes its commercial focus through therapies in sleep and related neurological markets.

That mix matters because small-cap biotech valuations often move more on product durability and trial progress than on broad market trends. For Vanda, the operating story still begins with its existing medicines.

Product focus

The company's best-known product is Hetlioz, a prescription treatment used for certain sleep-wake disorders. Vanda also markets Fanapt, an antipsychotic medicine, which broadens the revenue base beyond a single asset.

These products anchor the business while the company keeps investing in development programs. That gives the stock a profile that blends commercial execution with clinical risk.

Core medicines

Hetlioz remains the company's most recognizable brand, and Fanapt gives Vanda a second commercial pillar. Together they define the revenue engine while the research portfolio shapes the longer-term outlook.

That combination is typical of specialty pharma, where investors tend to watch prescription demand, patent durability and development updates. Vanda sits squarely in that framework.

Stock context

Vanda Pharmaceuticals trades on Nasdaq in US dollars. The stock is tied to the same market forces that shape many small-cap biotech names: pipeline expectations, product performance and regulatory risk.